ERCC1 polymorphisms in patients with advanced bladder cancer treated with platinum-based chemotherapy

被引：0
|
作者：
Bamias, A.
Nikitas, N.
Karadimou, A.
Gika, D.
Karavasilis, V.
Briasoulis, E. C.
Chrisofos, M.
Murray, S.
Pectasides, D. G.
Dimopoulos, M. A.
机构：
[1] Alexandra Peripheral Gen Hosp, Athens, Greece
[2] Univ Athens, Athens, Greece
[3] Univ Thessaloniki, GR-54006 Thessaloniki, Greece
[4] Hellen Cooperat Oncol Grp Data Off, Athens, Greece
[5] Metropolitan Hosp, Athens, Greece
[6] Univ Athens, Sch Med, Dept Therapeut, GR-11527 Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e15066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15066
引用
收藏
页数：1
相关论文
共 50 条
  • [21] ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy
    Ryu, Hyewon
    Song, Ik-Chan
    Choi, Yoon-Seok
    Yun, Hwan-Jung
    Jo, Deog-Yeon
    Kim, Jin Man
    Ko, Young Bok
    Lee, Hyo Jin
    MEDICINE, 2017, 96 (51)
  • [22] Predictive Effects of ERCC1 and XRCC3 SNP on Efficacy of Platinum-based Chemotherapy in Advanced NSCLC Patients
    Zhou, Caicun
    Ren, Shengxiang
    Zhou, Songwen
    Zhang, Ling
    Su, Cunxia
    Zhang, Zengli
    Deng, Qinfang
    Zhang, Jie
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 954 - 960
  • [23] Platinum-Based Chemotherapy in Lung Cancer Affects the Expression of Certain Biomarkers Including ERCC1
    Papay, Judit
    Sapi, Zoltan
    Egri, Gabor
    Marton Gyulai
    Szende, Bela
    Gyoergy Losonczy
    Jozsef Timar
    Moldvay, Judit
    PATHOLOGY & ONCOLOGY RESEARCH, 2009, 15 (03) : 445 - 450
  • [24] PLATINUM-BASED CHEMOTHERAPY IN LUNG CANCER AFFECTS THE EXPRESSION OF CERTAIN BIOMARKERS INCLUDING ERCC1
    Moldvay, J.
    Sapi, Z.
    Egri, G.
    Gyulai, M.
    Szende, B.
    Losonczy, G.
    Timar, J.
    Papay, J.
    LUNG CANCER, 2009, 64 : S31 - S31
  • [25] Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients
    Zhao, Xin
    Zhang, Zhiqiang
    Yuan, Yan
    Yuan, Xiaomei
    TUMOR BIOLOGY, 2014, 35 (08) : 8335 - 8341
  • [26] The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
    Song, Wenhui
    Ma, Hongshun
    ONCOTARGETS AND THERAPY, 2016, 9 : 3465 - 3471
  • [27] Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment
    Duran, Goretti
    Aguin, Santiago
    Cruz, Raquel
    Barros, Francisco
    Maria Giraldez, Jose
    Bernardez, Beatriz
    Lopez-Lopez, Rafael
    Carracedo, Angel
    Jesus Lamas, Maria
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2019, 41 (08): : 2704 - 2715
  • [28] ERCC1 and clinical resistance to platinum-based therapy
    Reed, E
    CLINICAL CANCER RESEARCH, 2005, 11 (17) : 6100 - 6102
  • [29] Higher Expression of ERCC1 May Be Associated with Resistance to Adjuvant Platinum-Based Chemotherapy in Gastric Cancer
    Wan, Jiayi
    Chao, Lin
    Lee, Arier C.
    Chen, Qi
    CANCER INVESTIGATION, 2017, 35 (02) : 85 - 91
  • [30] ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer
    Xu, Z. C.
    Cai, H. Z.
    Li, X.
    Xu, W. Z.
    Xu, T.
    Yu, B.
    Zou, Q.
    Xu, L.
    GENETICS AND MOLECULAR RESEARCH, 2016, 15 (02):
12345